Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TAK-788
- drug: Pemetrexed
- drug: Cisplatin
- drug: Carboplatin
Eligibility
Inclusion Criteria:
- Male or female adult patients (aged 18 years or older)
- Histologically or cytologically confirmed nonsquamous cell locally advanced not
suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC
- Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation
assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites)
or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion
mutation can be either alone or in combination with other EGFR or human epidermal
growth factor receptor 2 (HER2) mutations except EGFR mutations for which there are
approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M,
L861Q, G719X, or S768I, where X is any other amino acid)
- Adequate tumor tissue available, either from primary or metastatic sites, for central
laboratory confirmation of EGFR exon 20 insertion mutation
- At least 1 measurable lesion per RECIST Version 1.1
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ and hematologic function as defined by blood transfusions with a
recommended >/ 14 day washout period.
Exclusion Criteria:
- Received prior systemic treatment for locally advanced or metastatic disease,
including local administration, such as intra-pleural injection of anticancer
medication with the exception noted below:
- Neoadjuvant or adjuvant chemotherapy/immune therapy for Stage I to III or
combined modality chemotherapy/radiation for locally advanced disease is allowed
if completed >6 months before the development of metastatic disease.
- Received radiotherapy ≤14 days before randomization or has not recovered from
radiotherapy-related toxicities
- Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong
CYP3A inducer within 10 days before first dose of TAK-788
- Have been diagnosed with another primary malignancy other than NSCLC
- Have current spinal cord compression or leptomeningeal disease
- Have uncontrolled hypertension. Participants with hypertension should be under
treatment on study entry to control blood pressure
- Received a live vaccine within 4 weeks before randomization per Summary of product
characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
- Taking medication(s) known to be associated with the development of torsades de
pointes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard A. Quick
650-723-2983
I'm interested
Psoriasis Clinical Trials
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TAK-788
- drug: Pemetrexed
- drug: Cisplatin
- drug: Carboplatin
Eligibility
Inclusion Criteria:
- Male or female adult patients (aged 18 years or older)
- Histologically or cytologically confirmed nonsquamous cell locally advanced not
suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC
- Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation
assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites)
or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion
mutation can be either alone or in combination with other EGFR or human epidermal
growth factor receptor 2 (HER2) mutations except EGFR mutations for which there are
approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M,
L861Q, G719X, or S768I, where X is any other amino acid)
- Adequate tumor tissue available, either from primary or metastatic sites, for central
laboratory confirmation of EGFR exon 20 insertion mutation
- At least 1 measurable lesion per RECIST Version 1.1
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ and hematologic function as defined by blood transfusions with a
recommended >/ 14 day washout period.
Exclusion Criteria:
- Received prior systemic treatment for locally advanced or metastatic disease,
including local administration, such as intra-pleural injection of anticancer
medication with the exception noted below:
- Neoadjuvant or adjuvant chemotherapy/immune therapy for Stage I to III or
combined modality chemotherapy/radiation for locally advanced disease is allowed
if completed >6 months before the development of metastatic disease.
- Received radiotherapy ≤14 days before randomization or has not recovered from
radiotherapy-related toxicities
- Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong
CYP3A inducer within 10 days before first dose of TAK-788
- Have been diagnosed with another primary malignancy other than NSCLC
- Have current spinal cord compression or leptomeningeal disease
- Have uncontrolled hypertension. Participants with hypertension should be under
treatment on study entry to control blood pressure
- Received a live vaccine within 4 weeks before randomization per Summary of product
characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
- Taking medication(s) known to be associated with the development of torsades de
pointes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard A. Quick
650-723-2983
I'm interested
Dermatology Clinical Trials
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TAK-788
- drug: Pemetrexed
- drug: Cisplatin
- drug: Carboplatin
Eligibility
Inclusion Criteria:
- Male or female adult patients (aged 18 years or older)
- Histologically or cytologically confirmed nonsquamous cell locally advanced not
suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC
- Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation
assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites)
or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion
mutation can be either alone or in combination with other EGFR or human epidermal
growth factor receptor 2 (HER2) mutations except EGFR mutations for which there are
approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M,
L861Q, G719X, or S768I, where X is any other amino acid)
- Adequate tumor tissue available, either from primary or metastatic sites, for central
laboratory confirmation of EGFR exon 20 insertion mutation
- At least 1 measurable lesion per RECIST Version 1.1
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ and hematologic function as defined by blood transfusions with a
recommended >/ 14 day washout period.
Exclusion Criteria:
- Received prior systemic treatment for locally advanced or metastatic disease,
including local administration, such as intra-pleural injection of anticancer
medication with the exception noted below:
- Neoadjuvant or adjuvant chemotherapy/immune therapy for Stage I to III or
combined modality chemotherapy/radiation for locally advanced disease is allowed
if completed >6 months before the development of metastatic disease.
- Received radiotherapy ≤14 days before randomization or has not recovered from
radiotherapy-related toxicities
- Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong
CYP3A inducer within 10 days before first dose of TAK-788
- Have been diagnosed with another primary malignancy other than NSCLC
- Have current spinal cord compression or leptomeningeal disease
- Have uncontrolled hypertension. Participants with hypertension should be under
treatment on study entry to control blood pressure
- Received a live vaccine within 4 weeks before randomization per Summary of product
characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
- Taking medication(s) known to be associated with the development of torsades de
pointes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard A. Quick
650-723-2983
I'm interested
Pediatric Dermatology Clinical Trials
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TAK-788
- drug: Pemetrexed
- drug: Cisplatin
- drug: Carboplatin
Eligibility
Inclusion Criteria:
- Male or female adult patients (aged 18 years or older)
- Histologically or cytologically confirmed nonsquamous cell locally advanced not
suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC
- Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation
assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites)
or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion
mutation can be either alone or in combination with other EGFR or human epidermal
growth factor receptor 2 (HER2) mutations except EGFR mutations for which there are
approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M,
L861Q, G719X, or S768I, where X is any other amino acid)
- Adequate tumor tissue available, either from primary or metastatic sites, for central
laboratory confirmation of EGFR exon 20 insertion mutation
- At least 1 measurable lesion per RECIST Version 1.1
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ and hematologic function as defined by blood transfusions with a
recommended >/ 14 day washout period.
Exclusion Criteria:
- Received prior systemic treatment for locally advanced or metastatic disease,
including local administration, such as intra-pleural injection of anticancer
medication with the exception noted below:
- Neoadjuvant or adjuvant chemotherapy/immune therapy for Stage I to III or
combined modality chemotherapy/radiation for locally advanced disease is allowed
if completed >6 months before the development of metastatic disease.
- Received radiotherapy ≤14 days before randomization or has not recovered from
radiotherapy-related toxicities
- Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong
CYP3A inducer within 10 days before first dose of TAK-788
- Have been diagnosed with another primary malignancy other than NSCLC
- Have current spinal cord compression or leptomeningeal disease
- Have uncontrolled hypertension. Participants with hypertension should be under
treatment on study entry to control blood pressure
- Received a live vaccine within 4 weeks before randomization per Summary of product
characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
- Taking medication(s) known to be associated with the development of torsades de
pointes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard A. Quick
650-723-2983
I'm interested
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TAK-788
- drug: Pemetrexed
- drug: Cisplatin
- drug: Carboplatin
Eligibility
Inclusion Criteria:
- Male or female adult patients (aged 18 years or older)
- Histologically or cytologically confirmed nonsquamous cell locally advanced not
suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC
- Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation
assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites)
or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion
mutation can be either alone or in combination with other EGFR or human epidermal
growth factor receptor 2 (HER2) mutations except EGFR mutations for which there are
approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M,
L861Q, G719X, or S768I, where X is any other amino acid)
- Adequate tumor tissue available, either from primary or metastatic sites, for central
laboratory confirmation of EGFR exon 20 insertion mutation
- At least 1 measurable lesion per RECIST Version 1.1
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ and hematologic function as defined by blood transfusions with a
recommended >/ 14 day washout period.
Exclusion Criteria:
- Received prior systemic treatment for locally advanced or metastatic disease,
including local administration, such as intra-pleural injection of anticancer
medication with the exception noted below:
- Neoadjuvant or adjuvant chemotherapy/immune therapy for Stage I to III or
combined modality chemotherapy/radiation for locally advanced disease is allowed
if completed >6 months before the development of metastatic disease.
- Received radiotherapy ≤14 days before randomization or has not recovered from
radiotherapy-related toxicities
- Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong
CYP3A inducer within 10 days before first dose of TAK-788
- Have been diagnosed with another primary malignancy other than NSCLC
- Have current spinal cord compression or leptomeningeal disease
- Have uncontrolled hypertension. Participants with hypertension should be under
treatment on study entry to control blood pressure
- Received a live vaccine within 4 weeks before randomization per Summary of product
characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
- Taking medication(s) known to be associated with the development of torsades de
pointes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard A. Quick
650-723-2983
I'm interested
TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations
The purpose of this study is to compare the effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.
Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: TAK-788
- drug: Pemetrexed
- drug: Cisplatin
- drug: Carboplatin
Eligibility
Inclusion Criteria:
- Male or female adult patients (aged 18 years or older)
- Histologically or cytologically confirmed nonsquamous cell locally advanced not
suitable for definitive therapy, recurrent, or metastatic (Stage IV) NSCLC
- Documented epidermal growth factor receptor (EGFR) in-frame exon 20 insertion mutation
assessed by a clinical laboratory improvements amendment (CLIA)-certified (US sites)
or an accredited (outside of the US) local laboratory The EGFR exon 20 insertion
mutation can be either alone or in combination with other EGFR or human epidermal
growth factor receptor 2 (HER2) mutations except EGFR mutations for which there are
approved anti-EGFR tyrosine kinase inhibitors [TKIs] (ie, exon 19 del, L858R, T790M,
L861Q, G719X, or S768I, where X is any other amino acid)
- Adequate tumor tissue available, either from primary or metastatic sites, for central
laboratory confirmation of EGFR exon 20 insertion mutation
- At least 1 measurable lesion per RECIST Version 1.1
- Life expectancy ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Adequate organ and hematologic function as defined by blood transfusions with a
recommended >/ 14 day washout period.
Exclusion Criteria:
- Received prior systemic treatment for locally advanced or metastatic disease,
including local administration, such as intra-pleural injection of anticancer
medication with the exception noted below:
- Neoadjuvant or adjuvant chemotherapy/immune therapy for Stage I to III or
combined modality chemotherapy/radiation for locally advanced disease is allowed
if completed >6 months before the development of metastatic disease.
- Received radiotherapy ≤14 days before randomization or has not recovered from
radiotherapy-related toxicities
- Received a moderate or strong cytochrome P450 (CYP)3A inhibitor or moderate or strong
CYP3A inducer within 10 days before first dose of TAK-788
- Have been diagnosed with another primary malignancy other than NSCLC
- Have current spinal cord compression or leptomeningeal disease
- Have uncontrolled hypertension. Participants with hypertension should be under
treatment on study entry to control blood pressure
- Received a live vaccine within 4 weeks before randomization per Summary of product
characteristics (SmPCs) for pemetrexed, cisplatin, and carboplatin
- Taking medication(s) known to be associated with the development of torsades de
pointes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Richard A. Quick
650-723-2983
I'm interested